Table 1 Demographic and clinical characteristics of the study participants
From: APACHE-II score for anti-tuberculosis tolerance in critically ill patients: a retrospective study
Parameter | Drug withdrawal group (n = 147) | Therapy completion group (n = 173) | P |
|---|---|---|---|
Demographic characteristics | |||
 Age (years) | 65 (2–94) | 62 (17–90) | 0.24 |
 Male | 118 (80.3%) | 138 (79.8%) | 0.91 |
Tuberculosis characteristics | |||
 Pulmonary tuberculosis | 131 (89.1%) | 153 (88.4%) | 0.85 |
 Sputum smear positive | 98 (66.7%) | 105 (60.7%) | 0.27 |
 Extrapulmonary tuberculosis | 51 (34.7%) | 83 (48.05) | 0.02 |
 First treatment | 116 (78.9%) | 145 (83.8%) | 0.26 |
Comorbidities | |||
 Diabetes mellitus | 26 (17.7%) | 32 (18.5%) | 0.85 |
 Hypertension | 42 (28.6%) | 40 (23.1%) | 0.27 |
 Coronary heart disease | 23 (15.6%) | 17 (9.8%) | 0.12 |
 Chronic heart failure | 37 (25.2%) | 33 (19.1%) | 0.19 |
 Atrial fibrillation | 12 (8.2%) | 9 (5.2%) | 0.29 |
 Chronic renal failure | 14 (9.5%) | 7 (4.0%) | 0.049 |
 Lung cancer | 3 (2.0%) | 5 (2.9%) | 0.63 |
 Other malignant tumors | 12 (8.2%) | 10 (5.8%) | 0.40 |
 COPD | 31 (21.1%) | 21 (12.1%) | 0.03 |
 Bronchiectasis | 5 (3.4%) | 4 (2.3%) | 0.56 |
 Autoimmune disease | 12 (8.2%) | 15 (8.7%) | 0.87 |
 Neurological disorders | 20 (13.6%) | 18 (10.4%) | 0.38 |
 Viral hepatitis B | 7 (4.8%) | 14 (8.1%) | 0.23 |
Previous medical interventions | |||
 Long-term steroids | 12 (8.2%) | 12 (6.9%) | 0.68 |
 Long-term immunosuppressants | 2 (1.4%) | 4 (2.3%) | 0.53 |
 Mechanical ventilation | 119 (81.0%) | 124 (71.7%) | 0.053 |
Blood test results | |||
 White blood cell (109/L) | 9.8 (1.5–35.5) | 10.4 (0.4–41.2) | 0.27 |
 Platelet (109/L) | 158 (2–576) | 193 (12–723) | 0.06 |
 Hemoglobin (g/L) | 92 (41–150) | 104 (38–160) | 0.001 |
 Total bilirubin (μmol/L) | 12.1 (2.5–269.6) | 12.9 (1–92.2) | 0.40 |
 Direct bilirubin (μmol/L) | 5.8 (0.1–131.4) | 6.6 (0.1–65.1) | 0.24 |
 Indirect bilirubin (μmol/L) | 5.1 (0.3–138.2) | 5.4 (0.1–49) | 0.54 |
 Uric acid (μmol/L) | 209 (29–1102) | 225 (1–831) | 0.21 |
 Urea nitrogen (mmol/L) | 6.4 (0.9–34.6) | 5.9 (1.4–75.8) | 0.07 |
 Total protein (g/L) | 57.3 (26–83) | 56.7 (30.1–84.3) | 0.62 |
 Albumin (g/L) | 27.3 (10.6–47.4) | 28.0 (15.4–47.0) | 0.15 |
 Globulin (g/L) | 28.4 (15.4–46) | 27.3 (10.7–50.6) | 0.08 |
 Aspartate aminotransferase (U/L) | 33 (7–1241) | 28 (6–2971) | 0.21 |
 Alanine aminotransferase (U/L) | 19 (3–461) | 22 (2–757) | 0.23 |
 Alkaline phosphatase (U/L) | 94 (28–393) | 84 (25–927) | 0.12 |
 Gamma-glutamyltransferase (U/L) | 49 (10–813) | 44 (10–991) | 0.92 |
 Prealbumin (mg/L) | 86 (4–272) | 105 (8–394) | 0.26 |
 Retinol binding protein (mg/L) | 12.0 (1.1–73.8) | 12.3 (0.5–66.0) | 0.51 |
 Fructosamine (mmol/L) | 1.47 (0.70–3.06) | 1.46 (0.81–4.02) | 0.62 |
 Immunoglobulin A (g/L) | 2.96 (0.50–8.82) | 2.75 (0.22–6.15) | 0.49 |
 Immunoglobulin G (g/L) | 12.5 (4.4–24.5) | 11.6 (3.0–25.8) | 0.19 |
 Immunoglobulin M (g/L) | 1.00 (0.35–3.39) | 0.93 (0.28–3.52) | 0.60 |
 Complement component C3 (g/L) | 0.77 (0.08–1.64) | 0.89 (0.20–2.51) | 0.15 |
 Complement component C4 (g/L) | 0.24 (0.02–0.47) | 0.25 (0.07–0.64) | 0.40 |
 Cancer antigen CA-125 (kU/L) | 86.0 (7.4–1977.2) | 74.3 (3.3–1241.5) | 0.54 |
 CD3 (%) | 63.0 (35.6–94.1) | 57.9 (26.3–90.5) | 0.09 |
 CD4 (%) | 33.6 (4.61–64.5) | 29.4 (6.67–73.1) | 0.02 |
 CD8 (%) | 22.3 (3.3–56.9) | 22.0 (4.66–76.2) | 0.81 |
 CD4/CD8 ratio | 1.54 (0.25–13.58) | 1.4 (0.13–11.01) | 0.23 |
 CD19 (%) | 9.3 (0.1–46.3) | 10.2 (0.3–48.3) | 0.27 |
 CD16 and CD56 (%) | 11.0 (0.17–43.6) | 11.5 (0.1–60.5) | 0.36 |
Illness severity scales | |||
 APACHE-II score | 21 (3–52) | 17 (4–42) | < 0.001 |
 SOFA score | 6 (0–17) | 5 (0–18) | 0.10 |